A recent study by Dr. Jordan Verplank, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the ...

Mitochondria In Motion Inc. has identified new N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives acting as mitofusin activators and reported to be useful for the treatment of Alzheimer’s, ...

An east Auckland teenager with a rare genetic condition is grateful for having received equipment that will make it easier ...

SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder that’s both progressive and incurable. But now, nerve specialists ...

OBJECTIVES Charcot-Marie-Tooth disease type I (CMT1) is a hereditary sensorimotor neuropathy causing variable degrees of handicap. The risk for relevant disability in respect to genetic counselling is ...

Much has been achieved in terms of understanding the complex clinical and genetic heterogeneity of Charcot-Marie-Tooth neuropathy (CMT). Since the identification of mutations ... Nevertheless, despite ...

Staff's lab is aimed at dissecting these phenomena to find preceding protein pathways that may be able to be targeted for neuroprotection. Hereditary peripheral neuropathy (Charcot-Marie-Tooth disease ...

French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.

Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions.

The SynGAP Research Fund 501(c)(3) has awarded a pair of grants to Dr. Clement Chow, a geneticist and Associate Professor in the Department of Human Genetics at the University of Utah. These grants ...

Sara McCready launched Gnome and Away Travel in February with her husband Kevin. Becoming a Hays Travel Explorer franchisee ...